Skiplinks


Main navigation:

Investment Banking


 

Content

Healthcare/ Chemicals

In this market environment, Sal. Oppenheim has established itself as one of the leading investment banks for growth companies and SMEs in German-speaking countries. With a large number of successfully concluded mandates, we are one of the Top names for M&A and capital market transactions in the healthcare/chemicals sector.

Our clients comprise listed international groups as well as SMEs, young growth companies, public hospital authorities, and financial investors. Together with the relevant product specialists, our team of experienced professionals will gladly advise you. In this regard, our independence, discretion and objectivity are the ideal cornerstones for professional and successful investment banking services. We offer support in the various phases of your company’s development, from strategic alignment to tailored financing solutions.

Clients served

We serve clients from the following sectors:

  • Biotechnology
  • Healthcare services
  • Medical technology
  • Pharma
  • Chemicals

top

Our expertise

  • Our advisory activities span the entire investment banking value chain
  • Experienced and effective team of professionals with industry and product knowledge, as well as research expertise
  • Specialist expertise in life sciences through involvement of scientists in relationship management and research
  • Knowledge of local specifics, excellent relationship contacts with key players and network in the healthcare sector

Track Record

July 2007: Sale of Borchers GmbH, by LANXESS AG – Sal. Oppenheim acted as advisor to the seller July 2007: Acquisition of Hexal Pharma GmbH by Jossa Arznei GmbH – Sal. Oppenheim acted as advisor to the seller March 2007: Initial Public Offering and placement of approx. 2.7 million shares (CHF 54 million) – Sal. Oppenheim acted as joint lead manager February  2007: Public tender offer to the minority shareholders of Serono – Sal. Oppenheim provided a fairness opinion to the board of directors of Merck Serono January 2007: International private placement of 39.7% of the share capital held by institutional investors – Sal. Oppenheim acted as sole lead manage

Move your mouse over the various references to see the details of the transactions. Click on “more” for the complete list of references.

more

top


Please do not hesitate to contact us

Dr. Jan zur Hausen

Dr. Jan zur Hausen,
Contact Healthcare
Phone +49 69 7134 5227
Send e-mail

Marc Schmitz

Marc Schmitz,
Contact Chemicals
Phone +49 69 7134 5295
Send e-mail